PlainRecalls
FDA Drug Critical Class I Ongoing

Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton, Ready to Use For Intravenous Infusion Only Preservative Free, Rx Only, Manufactured and Distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645, (Vial NDC 51754-2131-1; Carton NDC 51754-2131-4).

Reported: November 29, 2023 Initiated: October 18, 2023 #D-0117-2024

Product Description

Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton, Ready to Use For Intravenous Infusion Only Preservative Free, Rx Only, Manufactured and Distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645, (Vial NDC 51754-2131-1; Carton NDC 51754-2131-4).

Reason for Recall

Presence of Particulate Matter: Silicone

Details

Recalling Firm
Exela Pharma Sciences LLC
Units Affected
23,425 vials
Distribution
Nationwide
Location
Lenoir, NC

Frequently Asked Questions

What product was recalled?
Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton, Ready to Use For Intravenous Infusion Only Preservative Free, Rx Only, Manufactured and Distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645, (Vial NDC 51754-2131-1; Carton NDC 51754-2131-4).. Recalled by Exela Pharma Sciences LLC. Units affected: 23,425 vials.
Why was this product recalled?
Presence of Particulate Matter: Silicone
Which agency issued this recall?
This recall was issued by the FDA Drug on November 29, 2023. Severity: Critical. Recall number: D-0117-2024.